Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1119

1.

Updated results of a phase II randomized trial with high dose proton pump inhibitors and metronomic capecitabine as salvage treatment for patients with advanced gastrointestinal tumours.

Roberto M, Arrivi G, Milano A, D'Antonio C, Romiti A, Falcone R, Mazzuca F, Fais S, Marchetti P.

Ann Oncol. 2019 Jul;30 Suppl 4:iv43-iv44. doi: 10.1093/annonc/mdz155.159. Epub 2019 Dec 4. No abstract available.

PMID:
32085161
2.

A real-life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second-line therapy.

Parisi A, Cortellini A, Roberto M, Venditti O, Santini D, Dell'Aquila E, Stellato M, Marchetti P, Occhipinti M, Zoratto F, Mazzuca F, Tinari N, De Tursi M, Iezzi L, Natoli C, Ratti M, Pizzo C, Ghidini M, Ficorella C, Cannita K.

Ann Oncol. 2019 Jul;30 Suppl 4:iv27. doi: 10.1093/annonc/mdz155.100. Epub 2019 Dec 4. No abstract available.

PMID:
32085103
3.

Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification.

Mazzotta M, Filetti M, Rossi A, Roberto M, Occhipinti M, Pernazza A, Di Napoli A, Scarpino S, Vecchione A, Giusti R, Marchetti P.

Ann Oncol. 2020 Mar;31(3):440-441. doi: 10.1016/j.annonc.2019.11.016. Epub 2019 Dec 9. No abstract available.

PMID:
32067689
4.

Adding pertuzumab to adjuvant therapy for high-risk HER2-positive early breast cancer in APHINITY: a GRADE analysis.

Zambelli A, Pappagallo G, Marchetti P.

J Comp Eff Res. 2020 Feb 14. doi: 10.2217/cer-2019-0168. [Epub ahead of print]

5.

Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.

Petrelli F, Labianca R, Zaniboni A, Lonardi S, Galli F, Rulli E, Rosati G, Corallo S, Ronzoni M, Cardellino GG, Mattioli R, Mambrini A, Ciuffreda L, Banzi M, Pusceddu V, Maiello E, Zampino M, Zagonel V, Marchetti P, Corsi D, Rimassa L, Cinieri S, Sobrero A.

JAMA Oncol. 2020 Feb 13. doi: 10.1001/jamaoncol.2019.6486. [Epub ahead of print]

PMID:
32053133
6.

[Cytotoxic lesion of the corpus callosum (CLOCC) in a context of viral meningitis].

Hoëffelin H, Marchetti P, Khamis J, Reginster P.

Rev Med Liege. 2020 Feb;75(2):78-82. French.

PMID:
32030930
7.

The Fascinating Chemistry of α-Haloamides.

Fantinati A, Zanirato V, Marchetti P, Trapella C.

ChemistryOpen. 2020 Jan 13;9(2):100-170. doi: 10.1002/open.201900220. eCollection 2020 Feb. Review.

8.

Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment.

Botticelli A, Vernocchi P, Marini F, Quagliariello A, Cerbelli B, Reddel S, Del Chierico F, Di Pietro F, Giusti R, Tomassini A, Giampaoli O, Miccheli A, Zizzari IG, Nuti M, Putignani L, Marchetti P.

J Transl Med. 2020 Feb 3;18(1):49. doi: 10.1186/s12967-020-02231-0.

9.

Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial.

Barni S, Rosati G, Lonardi S, Pella N, Banzi M, Zampino MG, Dotti KF, Rimassa L, Marchetti P, Maiello E, Artioli F, Ferrari D, Labianca R, Bidoli P, Zaniboni A, Sobrero A, Iaffaioli V, De Placido S, Frassineti GL, Ciarlo A, Buonadonna A, Silvestris N, Piazza E, Pavesi L, Moroni M, Clerico M, Aglietta M, Giordani P, Galli F, Galli F, Petrelli F.

Ther Adv Med Oncol. 2020 Jan 20;12:1758835919899850. doi: 10.1177/1758835919899850. eCollection 2020.

10.

Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study.

Cortellini A, Buti S, Bersanelli M, Giusti R, Perrone F, Di Marino P, Tinari N, De Tursi M, Grassadonia A, Cannita K, Tessitore A, Zoratto F, Veltri E, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Cappellini GCA, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Gelibter A, Occhipinti MA, Martella F, Inno A, Gori S, Bracarda S, Zannori C, Mosillo C, Parisi A, Porzio G, Mallardo D, Fargnoli MC, Tiseo M, Santini D, Ascierto PA, Ficorella C.

Oncoimmunology. 2020 Jan 7;9(1):1710389. doi: 10.1080/2162402X.2019.1710389. eCollection 2020.

11.

Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis.

Rosati G, Galli F, Cantore M, Bergamo F, Banzi M, Zampino MG, Mattioli R, Cardellino GG, Ronzoni M, Di Bartolomeo M, Tamberi S, Marchetti P, Rimassa L, Corsi D, Bochicchio AM, Artioli F, Labianca R, Galli F, Rulli E, Bilancia D, Bregni G; TOSCA (Three or Six Colon Adjuvant) Investigators.

Oncologist. 2020 Jan 13. doi: 10.1634/theoncologist.2019-0736. [Epub ahead of print]

12.

Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence.

Krasniqi E, Pizzuti L, Barchiesi G, Sergi D, Carpano S, Botti C, Kayal R, Sanguineti G, Marchetti P, Botticelli A, Marinelli D, Gamucci T, Natoli C, Grassadonia A, Tinari N, Tomao S, Tonini G, Santini D, Michelotti A, Mentuccia L, Vaccaro A, Magnolfi E, Gelibter A, Magri V, Cortesi E, D'Onofrio L, Cassano A, Cazzaniga M, Moscetti L, Fabbri A, Scinto AF, Corsi D, Carbognin L, Bria E, La Verde N, Garufi C, Di Stefano P, Mirabelli R, Veltri E, Paris I, Giotta F, Lorusso V, Landucci E, Ficorella C, Roselli M, Adamo V, Ricciardi G, Russo A, Valerio MR, Berardi R, Pistelli M, Cannita K, Zamagni C, Garrone O, Baldini E, Livi L, Meattini I, Del Medico P, Generali D, De Maria R, Risi E, Ciliberto G, Villa A, Sperduti I, Mazzotta M, Barba M, Giordano A, Vici P.

J Cell Physiol. 2020 Jan 15. doi: 10.1002/jcp.29445. [Epub ahead of print]

PMID:
31943171
13.

[Appropriate use of trastuzumab in Lazio Region: therapeutic scenarios and estimation of possible savings for the Regional Health Service.]

Belleudi V, Rosa AC, Musicco F, Marchetti P, Martini N, Andriani A, Calamia T, Addis A.

Recenti Prog Med. 2019 Dec;110(12):604-614. doi: 10.1701/3278.32519. Italian.

PMID:
31909763
14.

[Immunotherapy in non-small cell lung cancer patients: back to the future.]

Roberto M, Botticelli A, Cecere F, Cognetti F, Giusti R, Gelibter A, Lugini A, Nelli F, Nuti M, Santini D, Marchetti P.

Recenti Prog Med. 2019 Dec;110(12):587-593. doi: 10.1701/3278.32517. Italian.

PMID:
31909761
15.

'Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation' by Braaten et al: another point of view.

Ceccarelli F, Botticelli A, Gelibter AJ, Leccese I, Lucchetti R, Cortesi E, Valesini G, Marchetti P, Conti F.

Ann Rheum Dis. 2020 Jan 6. pii: annrheumdis-2019-216867. doi: 10.1136/annrheumdis-2019-216867. [Epub ahead of print] No abstract available.

PMID:
31907163
16.

Pro-inflammatory cytokines induce cell death, inflammatory responses, and endoplasmic reticulum stress in human iPSC-derived beta cells.

Demine S, Schiavo AA, Marín-Cañas S, Marchetti P, Cnop M, Eizirik DL.

Stem Cell Res Ther. 2020 Jan 3;11(1):7. doi: 10.1186/s13287-019-1523-3.

17.

Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program.

Baldini E, Lunghi A, Cortesi E, Turci D, Signorelli D, Stati V, Melotti B, Ricciuti B, Frassoldati A, Romano G, Ceresoli GL, Illiano A, Verderame F, Fasola G, Ricevuto E, Marchetti P, Pinto C, Cartenì G, Scotti V, Tibaldi C, Fioretto L, Giannarelli D.

Lung Cancer. 2020 Feb;140:59-64. doi: 10.1016/j.lungcan.2019.12.014. Epub 2019 Dec 20.

PMID:
31881412
18.

Exenatide induces frataxin expression and improves mitochondrial function in Friedreich ataxia.

Igoillo-Esteve M, Oliveira AF, Cosentino C, Fantuzzi F, Demarez C, Toivonen S, Hu A, Chintawar S, Lopes M, Pachera N, Cai Y, Abdulkarim B, Rai M, Marselli L, Marchetti P, Tariq M, Jonas JC, Boscolo M, Pandolfo M, Eizirik DL, Cnop M.

JCI Insight. 2020 Jan 30;5(2). pii: 134221. doi: 10.1172/jci.insight.134221.

19.

A nanobody-based nuclear imaging tracer targeting dipeptidyl peptidase 6 to determine the mass of human beta cell grafts in mice.

Demine S, Garcia Ribeiro R, Thevenet J, Marselli L, Marchetti P, Pattou F, Kerr-Conte J, Devoogdt N, Eizirik DL.

Diabetologia. 2019 Dec 23. doi: 10.1007/s00125-019-05068-5. [Epub ahead of print]

PMID:
31873789
20.

CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer.

Cerbelli B, Botticelli A, Pisano A, Pernazza A, Campagna D, De Luca A, Ascierto PA, Pignataro MG, Pelullo M, Rocca CD, Marchetti P, Fortunato L, Costarelli L, d'Amati G.

Virchows Arch. 2019 Dec 18. doi: 10.1007/s00428-019-02722-6. [Epub ahead of print]

PMID:
31853625
21.

Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity.

Frassoldati A, Biganzoli L, Bordonaro R, Cinieri S, Conte P, Laurentis M, Mastro LD, Gori S, Lauria R, Marchetti P, Michelotti A, Montemurro F, Naso G, Pronzato P, Puglisi F, Tondini CA.

Future Oncol. 2020 Feb;16(5):129-145. doi: 10.2217/fon-2018-0942. Epub 2019 Dec 18.

PMID:
31849236
22.

Influence of residential land cover on childhood allergic and respiratory symptoms and diseases: Evidence from 9 European cohorts.

Parmes E, Pesce G, Sabel CE, Baldacci S, Bono R, Brescianini S, D'Ippolito C, Hanke W, Horvat M, Liedes H, Maio S, Marchetti P, Marcon A, Medda E, Molinier M, Panunzi S, Pärkkä J, Polańska K, Prud'homme J, Ricci P, Snoj Tratnik J, Squillacioti G, Stazi MA, Maesano CN, Annesi-Maesano I.

Environ Res. 2019 Nov 22:108953. doi: 10.1016/j.envres.2019.108953. [Epub ahead of print]

23.

Stearoyl CoA desaturase is a gatekeeper that protects human beta cells against lipotoxicity and maintains their identity.

Oshima M, Pechberty S, Bellini L, Göpel SO, Campana M, Rouch C, Dairou J, Cosentino C, Fantuzzi F, Toivonen S, Marchetti P, Magnan C, Cnop M, Le Stunff H, Scharfmann R.

Diabetologia. 2020 Feb;63(2):395-409. doi: 10.1007/s00125-019-05046-x. Epub 2019 Dec 3.

24.

Thyroid disorders in programmed death 1 inhibitor-treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor?

Sbardella E, Tenuta M, Sirgiovanni G, Gianfrilli D, Pozza C, Venneri MA, Cortesi E, Marchetti P, Lenzi A, Gelibter AJ, Isidori AM.

Clin Endocrinol (Oxf). 2020 Mar;92(3):258-265. doi: 10.1111/cen.14135. Epub 2020 Jan 1.

PMID:
31788837
25.

Isometric Exercise Improves Redox Balance and Blood Pressure in Hypertensive Adults.

Olher RR, Rosa TS, Souza LHR, Oliveira JF, Soares BRA, Ribeiro TBA, Souza IRC, Neves RVP, Sousa CV, Deus LA, Marchetti PH, Simoes HG, Moraes MR.

Med Sci Sports Exerc. 2019 Nov 21. doi: 10.1249/MSS.0000000000002223. [Epub ahead of print]

PMID:
31764461
26.

Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios.

Pizzuti L, Krasniqi E, Barchiesi G, Mazzotta M, Barba M, Amodio A, Massimiani G, Pelle F, Kayal R, Vizza E, Grassadonia A, Tomao S, Venuti A, Gamucci T, Marchetti P, Natoli C, Sanguineti G, Ciliberto G, Vici P.

J Cancer. 2019 Oct 12;10(24):5903-5914. doi: 10.7150/jca.35109. eCollection 2019. Review.

27.

Cervical Spine Motion During Vehicle Extrication of Healthy Volunteers.

Gabrieli A, Nardello F, Geronazzo M, Marchetti P, Liberto A, Arcozzi D, Polati E, Cesari P, Zamparo P.

Prehosp Emerg Care. 2019 Dec 20:1-9. doi: 10.1080/10903127.2019.1695298. [Epub ahead of print]

PMID:
31750763
28.

Insulin Resistance as a Risk Factor for Cutaneous Melanoma. A Case Control Study and Risk-Assessment Nomograms.

Scoppola A, Strigari L, Barnabei A, Petasecca P, De Galitiis F, Fulgenzi CAM, Roselli M, De Lorenzo A, Di Renzo L, Marchetti P, Torino F.

Front Endocrinol (Lausanne). 2019 Nov 5;10:757. doi: 10.3389/fendo.2019.00757. eCollection 2019.

29.

Synthesis of N-acyl amide natural products using a versatile adenylating biocatalyst.

Marchetti PM, Richardson SM, Kariem NM, Campopiano DJ.

Medchemcomm. 2019 May 31;10(7):1192-1196. doi: 10.1039/c9md00063a. eCollection 2019 Jul 1.

30.

Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice.

Cortellini A, Vitale MG, De Galitiis F, Di Pietro FR, Berardi R, Torniai M, De Tursi M, Grassadonia A, Di Marino P, Santini D, Zeppola T, Anesi C, Gelibter A, Occhipinti MA, Botticelli A, Marchetti P, Rastelli F, Pergolesi F, Tudini M, Silva RR, Mallardo D, Vanella V, Ficorella C, Porzio G, Ascierto PA.

J Transl Med. 2019 Nov 15;17(1):376. doi: 10.1186/s12967-019-02132-x.

31.

Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment: a mono-institutional experience.

Valeriani M, Marinelli L, Macrini S, Reverberi C, Aschelter AM, De Sanctis V, Marchetti P, Tronnolone L, Osti MF.

Radiat Oncol. 2019 Nov 14;14(1):205. doi: 10.1186/s13014-019-1414-x.

32.

Atopy Modifies the Association Between Inhaled Corticosteroid Use and Lung Function Decline in Patients with Asthma.

Marcon A, Marchetti P, Antó JM, Cazzoletti L, Cerveri I, Corsico A, Ferreira DS, Garcia-Aymerich J, Gislason D, Heinrich J, Jõgi R, Johannessen A, Leynaert B, Malinovschi A, Pin I, Probst-Hensch N, Weyler J, Janson C, Jarvis D, Accordini S; Ageing Lungs in European Cohorts (ALEC) study.

J Allergy Clin Immunol Pract. 2019 Nov 5. pii: S2213-2198(19)30914-6. doi: 10.1016/j.jaip.2019.10.023. [Epub ahead of print]

33.

Chronic bronchitis without airflow obstruction, asthma and rhinitis are differently associated with cardiovascular risk factors and diseases.

Ferrari M, Piccinno E, Marcon A, Marchetti P, Cazzoletti L, Pirina P, Battaglia S, Grosso A, Squillacioti G, Antonicelli L, Verlato G, Pesce G.

PLoS One. 2019 Nov 7;14(11):e0224999. doi: 10.1371/journal.pone.0224999. eCollection 2019.

34.

The impact of proinflammatory cytokines on the β-cell regulatory landscape provides insights into the genetics of type 1 diabetes.

Ramos-Rodríguez M, Raurell-Vila H, Colli ML, Alvelos MI, Subirana-Granés M, Juan-Mateu J, Norris R, Turatsinze JV, Nakayasu ES, Webb-Robertson BM, Inshaw JRJ, Marchetti P, Piemonti L, Esteller M, Todd JA, Metz TO, Eizirik DL, Pasquali L.

Nat Genet. 2019 Nov;51(11):1588-1595. doi: 10.1038/s41588-019-0524-6. Epub 2019 Nov 1.

PMID:
31676868
35.

Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives.

Krasniqi E, Barchiesi G, Pizzuti L, Mazzotta M, Venuti A, Maugeri-Saccà M, Sanguineti G, Massimiani G, Sergi D, Carpano S, Marchetti P, Tomao S, Gamucci T, De Maria R, Tomao F, Natoli C, Tinari N, Ciliberto G, Barba M, Vici P.

J Hematol Oncol. 2019 Oct 29;12(1):111. doi: 10.1186/s13045-019-0798-2. Review.

36.

BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories.

Capoluongo E, La Verde N, Barberis M, Bella MA, Buttitta F, Carrera P, Colombo N, Cortesi L, Gion M, Guarneri V, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A, Gori S.

Diagnostics (Basel). 2019 Oct 9;9(4). pii: E146. doi: 10.3390/diagnostics9040146.

37.

4th ESPT Conference: pharmacogenomics and personalized medicine - research progress and clinical implementation.

Sipeky C, Llerena A, Manolopoulos VG, Pearson E, Mlakar V, Gozzo L, Simmaco M, Marchetti P, Re MD, Stankovic S, Meyer U, Cascorbi I, Ingelman-Sundberg M, Suarez-Kurtz G, Marc J, Katsila T, Paulmichl M, Nofziger C, Ansari M, Drago F, van Schaik RH.

Pharmacogenomics. 2019 Oct;20(15):1063-1069. doi: 10.2217/pgs-2019-0095.

PMID:
31588876
38.

Preliminary results of a counselling programme for fertility preservation in female cancer patients: The experience of the GEMME DORMIENTI network.

Ciccarone M, Hohaus S, Pulsoni A, Cavaceppi P, Franzò S, Fabbri R, Cudillo L, Battistini R, Di Rocco A, Annibali O, Cox MC, Provenzano I, Abruzzese E, Renzi D, Tesei C, Anticoli Borza P, Cuccaro A, Andriani A, D'Elia GM, Facchiano A, Marchetti P, Cantonetti M.

Eur J Cancer Care (Engl). 2020 Jan;29(1):e13174. doi: 10.1111/ecc.13174. Epub 2019 Sep 30.

PMID:
31571303
39.

Response to: Comment on "Impact of tumor site on the prognosis of small bowel adenocarcinoma".

Falcone R, Strigari L, Farina L, Marchetti P.

Tumori. 2019 Dec;105(6):532. doi: 10.1177/0300891619878898. Epub 2019 Sep 30. No abstract available.

PMID:
31570060
40.

Correction to: New paradigm for stage III melanoma: from surgery to adjuvant treatment.

Ascierto PA, Borgognoni L, Botti G, Guida M, Marchetti P, Mocellin S, Muto P, Palmieri G, Patuzzo R, Quaglino P, Stanganelli I, Caracò C.

J Transl Med. 2019 Sep 18;17(1):315. doi: 10.1186/s12967-019-2067-0.

41.

Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study.

Cazzaniga ME, Pinotti G, Montagna E, Amoroso D, Berardi R, Butera A, Cagossi K, Cavanna L, Ciccarese M, Cinieri S, Cretella E, De Conciliis E, Febbraro A, Ferraù F, Ferzi A, Fiorentini G, Fontana A, Gambaro AR, Garrone O, Gebbia V, Generali D, Gianni L, Giovanardi F, Grassadonia A, Leonardi V, Marchetti P, Melegari E, Musolino A, Nicolini M, Putzu C, Riccardi F, Santini D, Saracchini S, Sarobba MG, Schintu MG, Scognamiglio G, Spadaro P, Taverniti C, Toniolo D, Tralongo P, Turletti A, Valenza R, Valerio MR, Vici P, Clivio L, Torri V; VICTOR Study Group.

Breast. 2019 Dec;48:7-16. doi: 10.1016/j.breast.2019.07.006. Epub 2019 Aug 22.

PMID:
31470257
42.

Different Knee and Ankle Positions Affect Force and Muscle Activation During Prone Leg Curl in Trained Subjects.

Marchetti PH, Magalhaes RA, Gomes WA, da Silva JJ, Stecyk SD, Whiting WC.

J Strength Cond Res. 2019 Aug 29. doi: 10.1519/JSC.0000000000003333. [Epub ahead of print]

PMID:
31469769
43.

Antineoplastic drug occupational exposure: a new integrated approach to evaluate exposure and early genotoxic and cytotoxic effects by no-invasive Buccal Micronucleus Cytome Assay biomarker.

Ursini CL, Omodeo Salè E, Fresegna AM, Ciervo A, Jemos C, Maiello R, Buresti G, Colosio C, Rubino FM, Mandić-Rajčević S, Chiarella P, Carbonari D, Delrio P, Maiolino P, Marchetti P, Boccia R, Iavicoli S, Cavallo D.

Toxicol Lett. 2019 Nov;316:20-26. doi: 10.1016/j.toxlet.2019.08.022. Epub 2019 Aug 26.

PMID:
31465813
44.

Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results.

Facchini G, Rossetti S, Berretta M, Cavaliere C, Scagliarini S, Vitale MG, Ciccarese C, Di Lorenzo G, Palesandro E, Conteduca V, Basso U, Naglieri E, Farnesi A, Aieta M, Borsellino N, La Torre L, Iovane G, Bonomi L, Gasparro D, Ricevuto E, De Tursi M, De Vivo R, Lo Re G, Grillone F, Marchetti P, De Vita F, Scavelli C, Sini C, Pisconti S, Crispo A, Gebbia V, Maestri A, Galli L, De Giorgi U, Iacovelli R, Buonerba C, Cartenì G, D'Aniello C.

J Transl Med. 2019 Aug 29;17(1):296. doi: 10.1186/s12967-019-2047-4.

45.

Different volumes and intensities of static stretching affect the range of motion and muscle force output in well-trained subjects.

Marchetti PH, Miyatake MMS, Magalhaes RA, Gomes WA, Da Silva JJ, Brigatto FA, Zanini TCC, Behm DG.

Sports Biomech. 2019 Aug 29:1-10. doi: 10.1080/14763141.2019.1648540. [Epub ahead of print]

PMID:
31464179
46.

Sometimes, the Least Demanding Solution Is the Most Suitable: A Careful Survey of NMR Spectra of a Phosphonium Salt Accounted for Its "Unusual Wittig Reaction".

Fantinati A, Marchetti P, Trapella C, Zanirato V.

ACS Omega. 2018 Jul 19;3(7):8091-8096. doi: 10.1021/acsomega.8b01228. eCollection 2018 Jul 31.

47.

Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents.

Rossi A, Roberto M, Panebianco M, Botticelli A, Mazzuca F, Marchetti P.

Eur J Pharmacol. 2019 Nov 5;862:172621. doi: 10.1016/j.ejphar.2019.172621. Epub 2019 Aug 22. Review.

48.

Benefits of cryopreserved human amniotic membranes in association with conventional treatments in the management of full-thickness burns.

Hatzfeld AS, Pasquesoone L, Germain N, Danzé PM, Drucbert AS, Tardivel M, Bongiovanni A, Duquennoy-Martinot V, Guerreschi P, Marchetti P.

Int Wound J. 2019 Dec;16(6):1354-1364. doi: 10.1111/iwj.13198. Epub 2019 Aug 19.

PMID:
31429202
49.

New paradigm for stage III melanoma: from surgery to adjuvant treatment.

Ascierto PA, Borgognoni L, Botti G, Guida M, Marchetti P, Mocellin S, Muto P, Palmieri G, Patuzzo R, Quaglino P, Stanganelli I, Caracò C.

J Transl Med. 2019 Aug 14;17(1):266. doi: 10.1186/s12967-019-2012-2. Review. Erratum in: J Transl Med. 2019 Sep 18;17(1):315.

50.

Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes.

Cortellini A, Leonetti A, Catino A, Pizzutillo P, Ricciuti B, De Giglio A, Chiari R, Bordi P, Santini D, Giusti R, De Tursi M, Brocco D, Zoratto F, Rastelli F, Citarella F, Russano M, Filetti M, Marchetti P, Berardi R, Torniai M, Cortinovis D, Sala E, Maggioni C, Follador A, Macerelli M, Nigro O, Tuzi A, Iacono D, Migliorino MR, Banna G, Porzio G, Cannita K, Ferrara MG, Bria E, Galetta D, Ficorella C, Tiseo M.

Clin Transl Oncol. 2019 Aug 7. doi: 10.1007/s12094-019-02193-w. [Epub ahead of print]

PMID:
31392645

Supplemental Content

Loading ...
Support Center